✉news WorldEU Politics first seen 1 h ago, last 42 min ago, peak #9
EU approves first drug for cerebral adrenoleukodystrophy
Original: European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease
The European Commission has granted marketing authorization for NEZGLYAL (leriglitazone), making it the first pharmacological treatment approved for cerebral adrenoleukodystrophy, a rare and often fatal neurodegenerative disease affecting the brain. The decision offers a new option for patients who previously had no approved drug therapy, and it is being noted as a significant milestone in treatment of rare pediatric neurodegenerative conditions.
Why now: The approval marks the first ever authorized drug treatment for a rare disease that previously had none.
European CommissionNEZGLYALleriglitazone
Rank over time, top of the chart is #1. 2 snapshots from 1 h ago to 42 min ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/8762